Funding for this research was provided by:
National Institutes of Health (R01 CA158167, R01 CA227473, P50 CA121974, R01 CA196660, CA204002)
Foundation for the National Institutes of Health (K24 CA172123)
Received: 25 January 2019
Accepted: 7 May 2019
First Online: 14 June 2019
Ethics approval and consent to participate
: Patient specimens were de-identified. Animal experiments were approved by Yale IACUC.
: Not applicable.
: MB and WD have served as consultants for Eli Lilly and Company. WD has research funding from Pfizer. HK has received consulting fees from Roche-Genentech, Immunocore, Merck, Alexion, Celldex, Pfizer, Corvus, Biodesix and Nektar, and research funds to her institution from Merck, Bristol Myers Squibb and Apexigen, all outside of the submitted work.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.